Andrei R. Shustov

Hematology

825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Journal: Blood cancer journal

Published: January 28, 2026

Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma.

Autologous and allogeneic hematopoietic cell transplantation in children and adults with high-risk anaplastic large cell lymphoma.

Journal: Frontiers in oncology

Published: January 11, 2026

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Journal: Blood cancer journal

Published: September 05, 2024

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.

Journal: Blood advances

Published: July 17, 2024

Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.

Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.

Journal: Blood advances

Published: January 10, 2024

Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.

Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.

Journal: Transplantation and cellular therapy

Published: December 08, 2023

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma

Published: March 20, 2023

Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.

Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.

Journal: Cancer

Published: October 21, 2021

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 26, 2021

Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome.

Fatal Microangiopathic Hemolytic Anemia Due to Sézary Syndrome.

Journal: Cureus

Published: June 06, 2021

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.

Journal: The Lancet. Haematology

Published: April 12, 2021

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

Journal: The Lancet. Haematology

Published: April 09, 2021

Showing 1-12 of 92

Last Updated: 09/26/2026